In a phase 2 trial of a novel antihypertensive agent, multiple doses lowered plasma angiotensinogen to a greater extent than a single dose, but did not provide further blood pressure lowering, ...
Tonlamarsen “suppresses hepatic angiotensinogen production,” Laffin told the media ahead of the late-breaking session. “We know that AGT suppression reduces blood pressure among patients taking zero ...
Monthly injections of tonlamarsen lowered AGT but didn’t reduce BP in patients already on multiple antihypertensive drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results